Caplin Point Laboratories Limited
CAPLIPOINT · General/Diversified · NSE
₹1,765
Current Market Price
Fair Value (DCF)
₹1,805
Margin of Safety
+2.3%
Updated just now
YieldIQ Score
66/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
49%
ROE
18.6%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.13 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
23.3%
Return on capital employed
EV / EBITDA
15.8×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
1110.5×
EBIT covers interest
Current Ratio
6.97×
Short-term liquidity
Asset Turnover
0.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.5%
3-year revenue growth
Revenue CAGR (5Y)
13.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,764.9
Bear case
₹946.03
MoS -86.6%
Base case
₹1,804.73
MoS +2.2%
Bull case
₹2,243.95
MoS +21.3%
Ratio Trends
CAPLIPOINT · last 8 annual periods
ROE
18.6%
ROCE
25.7%
Operating Margin
—
Debt / Equity
0.00×
PE
44.7×
EV / EBITDA
8.8×
Historical Financials
CAPLIPOINT · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1061 Cr | ₹1269 Cr | ₹1467 Cr | ₹1694 Cr | ₹1937 Cr | +16.2% |
| EBITDA | — | ₹433 Cr | ₹497 Cr | ₹619 Cr | ₹743 Cr | +14.4% |
| EBIT | ₹315 Cr | ₹387 Cr | ₹452 Cr | ₹565 Cr | — | +15.7% |
| PAT | ₹251 Cr | ₹308 Cr | ₹377 Cr | ₹461 Cr | ₹536 Cr | +20.8% |
| EPS (diluted) | ₹31.71 | ₹39.26 | ₹49.18 | ₹59.90 | — | +17.2% |
| CFO | ₹269 Cr | ₹337 Cr | ₹272 Cr | ₹311 Cr | ₹432 Cr | +12.6% |
| CapEx | — | — | — | — | ₹-192 Cr | — |
| FCF | — | — | — | — | ₹241 Cr | +0.0% |
| Total Assets | — | ₹1736 Cr | ₹2191 Cr | ₹2697 Cr | ₹3209 Cr | +16.6% |
| Total Debt | — | — | ₹3.4 Cr | ₹0.3 Cr | ₹5.0 Cr | +10.2% |
| Shareholders' Equity | — | — | ₹1880 Cr | ₹2316 Cr | ₹2886 Cr | +11.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CAPLIPOINT vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| ALIVUS ALIVUS | — | — | Pending | 17.2% | — |
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| APLLTD APLLTD | — | — | Pending | 11.2% | — |
| GRANULES GRANULES | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
16 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹22.50/sh
Last payout
2025-09-12
₹3.00
Peak payout
₹3.00
Trailing yield
0.34%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Caplin Point Laboratories Limited has a current price of 1764.90 and a fair value of 1804.73, with a 2.3% margin of safety, and ROCE and ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CAPLIPOINT →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CAPLIPOINT →
Compare
Head-to-head with peers
Compare CAPLIPOINT side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CAPLIPOINTNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.